Exelixis (NASDAQ:EXEL) reported Q1 EPS of $0.26, $0.13 better than the analyst estimate of $0.13. Revenue for the quarter came in at $356 million versus the consensus estimate of $374.75 million.
GUIDANCE:
Exelixis sees FY2022 revenue of $1.53-1.63 billion, versus the consensus of $1.64 billion.
Exelixis is maintaining the following previously provided financial guidance for fiscal year 2022:
Total revenues |
| $1.525 billion - $1.625 billion |
Net product revenues |
| $1.325 billion - $1.425 billion |
Cost of goods sold |
| 5% - 6% of net product revenues |
Research and development expenses (1) |
| $725 million - $775 million |
Selling, general and administrative expenses (2) |
| $400 million - $450 million |
Effective tax rate |
| 20% - 22% |